Erasca (ERAS) Revenue & Revenue Breakdown
Erasca Revenue Highlights
00
Erasca Revenue by Period
Erasca Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Erasca Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $5.58M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Erasca Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ARVN | Arvinas | $78.50M | $102.40M |
RLAY | Relay Therapeutics | $25.55M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
IPSC | Century Therapeutics | $2.23M | $791.00K |
PLRX | Pliant Therapeutics | $1.58M | - |
LIFE | aTyr Pharma | $353.00K | $235.00K |
KROS | Keros Therapeutics | $151.00K | $37.00K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
BDTX | Black Diamond Therapeutics | - | - |
CCCC | C4 Therapeutics | - | - |
GRCL | Gracell Bio | - | - |
NGM | NGM Biopharmaceuticals | - | $165.00K |
OLMA | Olema Pharmaceuticals | - | - |
ERAS | Erasca | - | - |
MLYS | Mineralys Therapeutics | - | - |
SANA | Sana Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
ZNTL | Zentalis Pharmaceuticals | - | - |
EWTX | Edgewise Therapeutics | - | - |